Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Key Highlights
- ➤TUDRIQEV™ now commercially available in the U.S. for advanced melanoma (REPL)
- ➤Healthcare providers can order TUDRIQEV™ for next day delivery
- ➤Objective response rate reached 24.2% in anti-PD-1-failed melanoma patients
- ➤Median duration of response was 14.1 months
- ➤Accelerated approval depends on confirmatory clinical benefit verification
Expert Statements
Sushil Patel, Chief Executive Officer of Replimune
“With TUDRIQEV now available, we have reached a critical milestone in bringing this therapy to patients with advanced melanoma who have been waiting for a new option”
Sushil Patel, Chief Executive Officer of Replimune
“I’m deeply proud of our team, who moved with urgency to put the infrastructure and comprehensive patient support services in place so that healthcare providers can access this therapy with next day delivery when their patients need it.”
WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
Get started
Create a free account to read the full story.